Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival
Oncotarget2012Vol. 3(6), pp. 620–628
Citations Over TimeTop 23% of 2012 papers
J. Scott Nystrom, John Hornberger, Gauri R. Varadhachary, R. J. Hornberger, Hialy Gutierrez, W. David Henner, Shawn Becker, Mahul B. Amin, Michael G. Walker
Abstract
In patients with difficult-to-diagnose cancers, GEP changed the working diagnosis and management for the majority of patients. Patients for whom the GEP test was ordered had longer median survival than that historically reported for patients enrolled in treatment trials for cancer of unknown primary.
Related Papers
- → Interleucinas na encefalopatia hipóxico-isquêmica(2003)14 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)